Brought to you by 
Roche and I-Mab form collaboration to study Tecentriq/TJD5 combination
26 Oct 2021
Executive Summary
I-Mab Biopharma agreed to combine its anti-CD73 bispecific antibody TJD5 with Roche’s PD-L1 antagonist Tecentriq (atezolizumab) in a Phase I trial of patients with advanced or metastatic solid tumors who are refractory to or intolerant to all available therapy. The partners will share rights generated by the alliance.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Trial Collaborations
- R&D (No Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche and I-Mab form collaboration to study Tecentriq/TJD5 combination
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice